A. Khan, M. Fortier, M.A.O.W. GROUP, Osteoporosis in menopause. J. Obstet. Gynaecol. Can. 36(9), 839–40 (2014)

Article  PubMed  Google Scholar 

A. Papaioannou, S. Morin, A.M. Cheung, S. Atkinson, J.P. Brown, S. Feldman et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182(17), 1864–1873 (2010)

Article  PubMed  PubMed Central  Google Scholar 

P.J. Bekker, D.L. Holloway, A.S. Rasmussen, R. Murphy, S.W. Martin, P.T. Leese et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J. Bone Min. Res. 19(7), 1059–1066 (2004)

Article  CAS  Google Scholar 

S.R. Cummings, J. San Martin, M.R. McClung, E.S. Siris, R. Eastell, I.R. Reid et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361(8), 756–765 (2009)

Article  CAS  PubMed  Google Scholar 

P.D. Miller, Denosumab: anti-RANKL antibody. Curr. Osteoporos. Rep. 7(1), 18–22 (2009)

Article  PubMed  Google Scholar 

S. Papapoulos, R. Chapurlat, C. Libanati, M.L. Brandi, J.P. Brown, E. Czerwiński et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J. Bone Min. Res. 27(3), 694–701 (2012)

Article  CAS  Google Scholar 

M.A. Bolognese, C.S. Teglbjærg, J.R. Zanchetta, K. Lippuner, M.R. McClung, M.L. Brandi et al. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. J. Clin. Densitom. 16(2), 147–153 (2013)

Article  PubMed  Google Scholar 

H.G. Bone, R.B. Wagman, M.L. Brandi, J.P. Brown, R. Chapurlat, S.R. Cummings et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5(7), 513–523 (2017)

Article  CAS  PubMed  Google Scholar 

A.A. Khan, A. Morrison, D.A. Hanley, D. Felsenberg, L.K. McCauley, F. O’Ryan et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Min. Res. 30(1), 3–23 (2015)

Article  Google Scholar 

E. Shane, D. Burr, B. Abrahamsen, R.A. Adler, T.D. Brown, A.M. Cheung et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J. Bone Min. Res. 29(1), 1–23 (2014)

Article  Google Scholar 

A.A. Khan, W.D. Leslie, B. Lentle, S. Iles, S.M. Kaiser, H. Frame et al. Atypical femoral fractures: a teaching perspective. Can. Assoc. Radio. J. 66(2), 102–107 (2015)

Article  Google Scholar 

E. Tsourdi, B. Langdahl, M. Cohen-Solal, B. Aubry-Rozier, E.F. Eriksen, N. Guañabens et al. Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105, 11–17 (2017)

Article  PubMed  Google Scholar 

E. Tsourdi, M.C. Zillikens, C. Meier, J.J. Body, E. Gonzalez Rodriguez, A.D. Anastasilakis, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J. Clin. Endocrinol. Metab 106(1), 264–281 (2021)

Article  Google Scholar 

H.G. Bone, M.A. Bolognese, C.K. Yuen, D.L. Kendler, P.D. Miller, Y.C. Yang et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96(4), 972–980 (2011)

Article  CAS  PubMed  Google Scholar 

S.R. Cummings, S. Ferrari, R. Eastell, N. Gilchrist, J.B. Jensen, M. McClung et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Min. Res. 33(2), 190–198 (2018)

Article  CAS  Google Scholar 

H. Lyu, K. Yoshida, S.S. Zhao, J. Wei, C. Zeng, S.K. Tedeschi et al. Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study. Ann. Intern. Med. 173(7), 516–26. (2020)

Article  PubMed  Google Scholar 

A.D. Anastasilakis, G. Evangelatos, P. Makras, A. Iliopoulos, Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. Bone Rep. 12, 100267 (2020). 2020/06/01/

Article  PubMed  PubMed Central  Google Scholar 

M. Kashii, K. Ebina, K. Kitaguchi, H. Yoshikawa, Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report. Bone Rep. 13, 100288 (2020)

Article  PubMed  PubMed Central  Google Scholar 

L. Tripto-Shkolnik, N. Fund, V. Rouach, G. Chodick, V. Shalev, I. Goldshtein, Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider. Bone 130, 115150 (2020)

Article  PubMed  Google Scholar 

E. Fernández Fernández, D. Benavent Núñez, G. Bonilla Hernán, I. Monjo Henry, S. García Carazo, M. Bernad Pineda et al. Multiple vertebral fractures following discontinuation of denosumab treatment: ten clinical cases report. Reumatol.ía Clín. 16(6), 480–484 (2020)

Article  Google Scholar 

H. Florez, J. Ramírez, A. Monegal, N. Guañabens, P. Peris, Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature. Semin. Arthritis Rheumatism 49(2), 197–203 (2019)

Article  CAS  PubMed  Google Scholar 

P. Anagnostis, S.A. Paschou, E. Gonzalez-Rodriguez, M. Potoupnis, E. Tsiridis, O. Lamy, et al. Spontaneous vertebral fractures in males with osteoporosis after denosumab discontinuation: a report of two cases. J. Clin. Rheumatol 7(8S), S581–S584 (2021).

Article  Google Scholar 

H. Che, V. Breuil, B. Cortet, J. Paccou, T. Thomas, L. Chapuis et al. Vertebral fractures cascade: potential causes and risk factors. Osteoporos. Int. 30(3), 555–63 (2019)

Article  CAS  PubMed  Google Scholar 

O. Lamy, E. Gonzalez-Rodriguez, D. Stoll, D. Hans, B. Aubry-Rozier, Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J. Clin. Endocrinol. Metab. 102(2), 354–358 (2017)

Article  PubMed  Google Scholar 

E. Gonzalez-Rodriguez, B. Aubry-Rozier, D. Stoll, D. Hans, O. Lamy, Clinical features of 35 patients with 172 spontaneous vertebral fractures after denosumab discontinuation: a single center observational study. J. Bone Miner. Res. 33,3–3 (Wiley, Nj USA, 2018)

A.D. Anastasilakis, S.A. Polyzos, P. Makras, B. Aubry-Rozier, S. Kaouri, O. Lamy, Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J. Bone Miner. Res. 32(6), 1291–1296 (2017)

Article  CAS  PubMed  Google Scholar 

E. Tsourdi, M.C. Zillikens, C. Meier, J.-J. Body, E. Gonzalez Rodriguez, A.D. Anastasilakis et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J. Clin. Endocrinol. Metab. 106(1), 264–281 (2021)

Article  Google Scholar 

J. Everts-Graber, S. Reichenbach, B. Gahl, H.R. Ziswiler, U. Studer, T. Lehmann, Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone 144, 115830 (2021)

Article  CAS  PubMed  Google Scholar 

A.M. Horne, B. Mihov, I.R. Reid, Bone loss after romosozumab/denosumab: effects of bisphosphonates. Calcif. Tissue Int. 103(1), 55–61 (2018). 2018-07-01

Article  CAS  PubMed  Google Scholar 

M. Laroche, G. Couture, A. Ruyssen-Witrand, A. Constantin, Y. Degboé, Effect of risedronate on bone loss at discontinuation of denosumab. Bone Rep. 13, 100290 (2020)

Article  PubMed  PubMed Central  Google Scholar 

O. Lamy, E. Fernández-Fernández, I. Monjo-Henry, D. Stoll, B. Aubry-Rozier, D. Benavent-Núñez et al. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports. Osteoporos. Int. 30(5), 1111–1115 (2019)

Article  CAS  PubMed  Google Scholar 

A.S. Sølling, T. Harsløf, B. Langdahl, Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J. Bone Min. Res. 10 35(10), 1858–1870 (2020)

Article  Google Scholar 

Sølling AS, Harsløf T, Langdahl B. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study. J Bone Miner Res. 36(7), 1245–1254 (2021) https://doi.org/10.1002/jbmr.4305. Epub 2021 Apr 20

J. Everts‐Graber, S. Reichenbach, H.R. Ziswiler, U. Studer, T. Lehmann, A Single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J. Bone Miner. Res. 35(7), 1207–15. (2020)

Article  PubMed  Google Scholar 

A.D. Anastasilakis, S.E. Papapoulos, S.A. Polyzos, N.M. Appelman‐Dijkstra, P. Makras, Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. a prospective 2‐year clinical trial. J. Bone Miner. Res. 34(12), 2220–2228 (2019)

Article  CAS  PubMed  Google Scholar 

E.M. Lewiecki, P.D. Miller, M.R. McClung, S.B. Cohen, M.A. Bolognese, Y. Liu et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J. Bone Min. Res 22(12), 1832–1841 (2007)

Article  CAS  Google Scholar 

P.D. Miller, M.A. Bolognese, E.M. Lewiecki, M.R. McClung, B. Ding, M. Austin et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43(2), 222–229 (2008). AugEpub 2008/04/26

Article  CAS  PubMed  Google Scholar 

M.M. McDonald, W.H. Khoo, P.Y. Ng, Y. Xiao, J. Zamerli, P. Thatcher et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184(5), 1330–1347.e13 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

(WHO) WHO. Handbook for Good Clinical Practice. Office of Publications, World Health Organization, Geneva, Switzer- land: WHO Library Cataloguing-in-Publication Data; (2002)

P. Makras, N.M. Appelman-Dijkstra, S.E. Papapoulos, S. Van Wissen, E.M. Winter, S.A. Polyzos et al. The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J. Clin. Endocrinol. Metab. 106(10), e4155–e4162 (2021)

Article  PubMed